Clinical Trial Update: Single Arm on the Tolerability of Weekly Nab-paclitaxel [Phase 2]

View source ↗

Summary

Phase 2 single-arm study evaluating tolerability of weekly nab-paclitaxel in NSCLC completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2020-10-08